Company Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
35.02 ^USD	+8.12%		+5.90%	+163.31%

06-14	Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing	MT
06-13	Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress	CI

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Number of employees: 143

Managers	Title	Age	Since
Jason Rhodes FOU	Founder	54	30/11/17
Rick Scalzo DFI	Director of Finance/CFO	38	30/11/19
John Najim CTO	Chief Tech/Sci/R&D Officer	48	31/07/19
Oxana Beskrovnaya CTO	Chief Tech/Sci/R&D Officer	63	26/01/20
Catherine Stehman-Breen CTO	Chief Tech/Sci/R&D Officer	61	27/06/19
Wildon Farwell CTO	Chief Tech/Sci/R&D Officer	49	03/03/21
Ashish Dugar CTO	Chief Tech/Sci/R&D Officer	-	07/02/21
Susanna High COO	Chief Operating Officer	56	30/06/20
Amy Reilly IRC	Investor Relations Contact	51	30/06/20
Daniel Wilson LAW	General Counsel	53	31/05/20

Members of the board	Title	Age	Since
Edward Hurwitz BRD	Director/Board Member	60	31/10/18
David Lubner BRD	Director/Board Member	60	29/02/20
Dirk Kersten BRD	Director/Board Member	49	31/10/18
Jason Rhodes FOU	Founder	54	30/11/17
Carlo Incerti BRD	Director/Board Member	65	01/03/22
Catherine Stehman-Breen CTO	Chief Tech/Sci/R&D Officer	61	27/06/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	99,164,649	98,702,810 ( 99.53 %)	0	99.53 %

Name	Equities	%	Valuation
Atlas Venture Life Science Advisors LLC 8.194 %	8,020,136	8.194 %	256 M $
Forbion Capital Partners Management Holding BV 8.015 %	7,845,364	8.015 %	250 M $
BlackRock Advisors LLC 5.161 %	5,051,344	5.161 %	161 M $
RA Capital Management LP 5.062 %	4,954,779	5.062 %	158 M $
Deep Track Capital LP 4.654 %	4,555,383	4.654 %	145 M $
Citadel Securities GP LLC 4.346 %	4,254,276	4.346 %	136 M $
STATE STREET CORPORATION 4.284 %	4,193,553	4.284 %	134 M $
MPM BioImpact, Inc 3.526 %	3,451,303	3.526 %	110 M $
Vanguard Fiduciary Trust Co. 3.515 %	3,440,270	3.515 %	110 M $
Fidelity Management & Research Co. LLC 3.288 %	3,218,393	3.288 %	103 M $

Dyne Therapeutics, Inc.

1560 Trapelo Road

02451, Waltham

http://www.dyne-tx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.02 USD

Average target price

45.9 USD

Spread / Average Target

+31.07%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
DYNE THERAPEUTICS, INC.	+163.31%	3.47B
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
CELLTRION, INC.	-12.11%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research